Gyre Therapeutics, Inc. Cash and Cash Equivalents
Gyre Therapeutics, Inc. (GYRE) had Cash and Cash Equivalents of $43.29 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-07
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $43.29M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $37.50M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $49.19M; Cash and Cash Equivalents, at Carrying Value as first filed $37.07M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $40.40M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $43.29M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $37.50M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $49.19M 10-Q · filed 2026-08-07 | $37.07M 10-K · filed 2026-03-13 |
| 2025-09-30 | $40.40M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $36.49M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $15.04M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $11.81M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $15.87M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $16.10M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $29.79M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $33.51M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $2.23M 10-Q · filed 2023-10-26 | |
| 2023-06-30 | $6.92M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $8.10M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $25.18M 10-K · filed 2024-03-27 | $21.67M 10-K · filed 2023-03-30 |
| 2022-09-30 | $23.09M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $75.39M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $34.82M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $44.35M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $59.16M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $73.62M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $83.04M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $30.36M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $24.92M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $59.27M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $70.36M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $15.37M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $23.02M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $17.35M 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $25.02M 10-Q · filed 2020-05-11 | |
| 2018-12-31 | $31.21M 10-K · filed 2020-02-20 | |
| 2018-09-30 | $36.00M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $46.53M 10-Q · filed 2019-08-01 | |
| 2018-03-31 | $126.55M 10-Q · filed 2019-05-02 | |
| 2017-12-31 | $14.47M 10-K · filed 2019-03-08 | |
| 2017-09-30 | $10.97M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $32.39M 10-Q · filed 2018-08-02 | |
| 2017-03-31 | $14.53M 10-Q · filed 2018-05-03 | |
| 2016-12-31 | $10.26M 10-K · filed 2018-03-19 | |
| 2016-09-30 | $9.32M 10-Q · filed 2017-11-02 | |
| 2016-06-30 | $11.33M 10-Q · filed 2017-08-03 | |
| 2016-03-31 | $20.58M 10-Q · filed 2017-05-11 | |
| 2015-12-31 | $29.10M 10-K · filed 2018-03-19 | |
| 2015-09-30 | $23.10M 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $2.31M 10-Q · filed 2016-08-04 | $78.20M 10-Q · filed 2015-07-31 |
| 2015-03-31 | $2.07M 10-Q · filed 2016-05-05 | $73.11M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $1.54M 10-K · filed 2017-03-08 | $56.43M 10-K · filed 2015-03-16 |
| 2014-09-30 | $3.60M 10-Q · filed 2015-11-05 | $45.71M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $4.23M 8-K/A · filed 2015-10-23 | $43.42M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $45.04M 10-Q · filed 2015-05-07 | |
| 2014-01-12 | $2.83M 10-Q · filed 2015-11-05 | |
| 2013-12-31 | $2.83M 10-K · filed 2016-03-09 | $54.48M 10-K · filed 2014-03-14 |
| 2013-09-30 | $61.74M 10-Q · filed 2014-11-06 | |
| 2013-06-30 | $63.06M 10-Q · filed 2014-08-07 | |
| 2013-03-31 | $69.86M 10-Q · filed 2014-05-08 | |
| 2012-12-31 | $3.40M 10-K · filed 2016-03-09 | $82.24M 10-K · filed 2013-03-15 |
| 2012-09-30 | $78.20M 10-Q · filed 2013-11-06 | |
| 2012-06-30 | $71.64M 10-Q · filed 2013-08-07 | |
| 2012-03-31 | $88.67M 10-Q · filed 2013-05-08 | |
| 2011-12-31 | $107.28M 10-K · filed 2015-03-16 | |
| 2011-09-30 | $130.54M 10-Q · filed 2012-11-08 | |
| 2011-06-30 | $168.14M 10-Q · filed 2012-08-09 | |
| 2011-03-31 | $138.84M 10-Q · filed 2012-05-09 | |
| 2010-12-31 | $165.85M 10-K · filed 2014-03-14 | |
| 2010-09-30 | $185.80M 10-Q · filed 2011-11-03 | |
| 2010-06-30 | $221.63M 10-Q · filed 2011-08-09 | |
| 2009-12-31 | $83.91M 10-K · filed 2013-03-15 | |
| 2008-12-31 | $51.20M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |